Two new drugs for homozygous familial hypercholesterolemia: Managing benefits and risks in a rare disorder

JAMA Internal Medicine

Volumn 173, Issue 16, 2013, Pages 1491-1492

  Smith, Robert J ^a,b   Hiatt, William R ^c,d  

^a BROWN UNIVERSITY   (United States)

^b PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d CPC Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; PLACEBO;

ADVISORY COMMITTEE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG COST; DRUG DOSE TITRATION; DRUG INHIBITION; DRUG SAFETY; FAMILIAL HYPERCHOLESTEROLEMIA; FATTY LIVER; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRANSAMINASEMIA; INJECTION SITE REACTION; LIVER CIRRHOSIS; LONG TERM EXPOSURE; PRIORITY JOURNAL; SHORT SURVEY;

ANTICHOLESTEREMIC AGENTS; BENZIMIDAZOLES; CHOLESTEROL, LDL; DRUG APPROVAL; FATTY LIVER; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; OLIGONUCLEOTIDES; PRODUCT SURVEILLANCE, POSTMARKETING; RARE DISEASES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84883787786     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.6624     Document Type: Short Survey

References (7)

1. Moorjani S, RoyM, Torres A, et al. Mutations of low-density-lipoprotein- receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolaemia. Lancet. 1993;341(8856):1303-1306. (Pubitemid 23148092)
2. Raal FJ, Pilcher GJ, Panz VR, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011;124(20):2202-2207.
3. Sachais BS, Katz J, Ross J, Rader DJ. Long-term effects of LDL apheresis in patients with severe hypercholesterolemia. J Clin Apher. 2005;20(4):252-255.
4. Cuchel M, Meagher EA, du Toit Theron H, et al; Phase 3 HoFH Lomitapide Study investigators. Efficacy and safety of amicrosomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381(9860):40-46.
5. Raal FJ, Santos RD, Blom DJ, et al.Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9719):998-1006.
6. Baigent C, Blackwell L, Emberson J, et al Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: ameta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681.
7. Gould AL, Davies GM, Alemao E, Yin DD, Cook JR. Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. Clin Ther. 2007;29(5):778-794. (Pubitemid 47225184)